GammaCore Sapphire, a new non-invasive hand-held device for migraine and episodic cluster headache treatment, has been made available by electroCore.
Teva has decided to discontinue part of the ENFORCE Phase 3 clinical development program for fremanezumab.
The episodic cluster headache trial included a total of 106 patients with an average of 17.5 cluster headache attacks per week at baseline.
Over half of all individuals included in this study reported headache attacks occurring at specific time periods throughout the day.
The 2 treatments for cluster headache with Level A recommendations are either not readily accessible via public or private insurance or are not recommended in a large subset of patients with cardiovascular disease.
Despite a recent study concluding that oxygen therapy for cluster headache is not cost-prohibitive, many private payers and Medicare and Medicaid do not cover the effective therapy. Matthew Robbins, MD, Stewart Tepper, MD, and others weigh in on the controversial decision.
Painful signs and symptoms frequently occur prior to cluster headache attacks.
The current costs of medical grade oxygen for treating cluster headache are not "prohibitively expensive."
Patients can receive the gammaCore device by participating in the gammaCore Patient Registry program.
A follow-up study revealed the benefits of sphenopalatine ganglion stimulation for the prevention of cluster headache attacks.
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
SPG stimulation is delivered on-demand through an implanted neurostimulator.
The therapy effects lasted for about a month, as researchers noted the procedure would need to be repeated for continuous relief.
The noninvasive device not only stopped acute attacks, but reduced overall headache frequency.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Unintended Pregnancy Common in Women With Epilepsy
- Aggressive Blood Pressure Lowering in Intracerebral Hemorrhage May Be Harmful
- Risk of Opioid-Benzodiazepine Overlap Up for Dual Prescribing
- Minority Residents Experience Burdens Linked to Race/Ethnicity
- Tips Provided for Budgeting in Medical Residency